CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Is Cardiac Diastolic Dysfunction a Part of Post-Menopausal Syndrome? Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failure Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction Heart Failure With Improved Ejection Fraction-Is it Possible to Escape One’s Past? Percutaneous Atriotomy for Levoatrial–to–Coronary Sinus Shunting in Symptomatic Heart Failure: First-in-Human Experience A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF) Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors

JOURNAL: Article Link

经皮冠状动脉介入治疗后的积极降脂治疗--目标人群以及如何开展?

作者:Zhen-Vin Lee等 译者:左广峰 审校:姜潇

摘要

尽管经皮冠状动脉介入治疗 (PCI) 对阻塞性冠状动脉疾病的疗效是确切的,但考虑到非手术相关的其他重要危险因素的控制程度,尚不能确保长期预后。动脉粥样硬化作为血脂异常的结果,其发展导致的风险具有连续性,因此对接受PCI的患者采取二级预防措施,对于降低手术失败以及心血管事件的风险尤为重要。本综述通过总结最新临床指南推荐,强调三种主流降脂疗法相关理论和证据(即他汀类药物、依折麦布和前蛋白转化酶枯草杆菌蛋白酶/ kexin 9型(PCSK9)抑制剂),概述以二级预防为目的降脂治疗现状。同时,揭示了血脂异常二级预防在实践过程中的挑战和问题,如对未达最佳血脂标准及依从性差等问题提出了可行性方案。